Shih-Fu Chang, Ph.D..
[更多]
The anti-CTLA-4 antibody, Ipilimumab, also known as YERVOY, was FDA approved for the treatment of metastatic melanoma in 2011. Ipilimumab works by inhibiting CTLA-4, a protein on T-cells that prevents them from attacking cancer cells. Only about 10-20% of melanoma patients respond to Ipilimumab. Sin.....
[更多]
The current technology proposes the use of a lentiviral vector to target specific human immune cells as well as certain types of cancer cells. The approach has been validated using a mouse model for metastatic melanoma [Morizono K, et. al, 2005. Lentiviral vector retargeting to P-Glycoprotein on met.....
[更多]
| |< <- | [3751] [3752] [3753] [3754] [3755] [3756] [3757] [3758] [3759] [3760] [3761] | -> >| |
